vs

Side-by-side financial comparison of INTERNATIONAL BANCSHARES CORP (IBOC) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

INTERNATIONAL BANCSHARES CORP is the larger business by last-quarter revenue ($217.7M vs $209.8M, roughly 1.0× MYRIAD GENETICS INC). On growth, INTERNATIONAL BANCSHARES CORP posted the faster year-over-year revenue change (4.5% vs -0.4%). Over the past eight quarters, INTERNATIONAL BANCSHARES CORP's revenue compounded faster (2.8% CAGR vs 1.9%).

International Bancshares Corporation is a bank holding company based in Laredo, Texas whose primary subsidiary is International Bank of Commerce. Through its bank subsidiaries, it has 217 banking offices and 315 automated teller machines serving 88 communities in the U.S. states of Texas and Oklahoma.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

IBOC vs MYGN — Head-to-Head

Bigger by revenue
IBOC
IBOC
1.0× larger
IBOC
$217.7M
$209.8M
MYGN
Growing faster (revenue YoY)
IBOC
IBOC
+4.9% gap
IBOC
4.5%
-0.4%
MYGN
Faster 2-yr revenue CAGR
IBOC
IBOC
Annualised
IBOC
2.8%
1.9%
MYGN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBOC
IBOC
MYGN
MYGN
Revenue
$217.7M
$209.8M
Net Profit
$106.9M
Gross Margin
70.0%
Operating Margin
62.8%
-2.7%
Net Margin
62.3%
Revenue YoY
4.5%
-0.4%
Net Profit YoY
-7.1%
EPS (diluted)
$1.71
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBOC
IBOC
MYGN
MYGN
Q4 25
$217.7M
$209.8M
Q3 25
$218.1M
$205.7M
Q2 25
$208.2M
$213.1M
Q1 25
$198.2M
$195.9M
Q4 24
$208.3M
$210.6M
Q3 24
$211.8M
$213.3M
Q2 24
$207.8M
$211.5M
Q1 24
$205.8M
$202.2M
Net Profit
IBOC
IBOC
MYGN
MYGN
Q4 25
$106.9M
Q3 25
$108.4M
$-27.4M
Q2 25
$100.1M
$-330.5M
Q1 25
$96.9M
$-100.0K
Q4 24
$115.1M
Q3 24
$99.8M
$-22.1M
Q2 24
$97.0M
$-36.7M
Q1 24
$97.3M
$-26.0M
Gross Margin
IBOC
IBOC
MYGN
MYGN
Q4 25
70.0%
Q3 25
69.9%
Q2 25
71.2%
Q1 25
68.5%
Q4 24
71.7%
Q3 24
70.2%
Q2 24
69.6%
Q1 24
68.1%
Operating Margin
IBOC
IBOC
MYGN
MYGN
Q4 25
62.8%
-2.7%
Q3 25
62.6%
-11.3%
Q2 25
60.5%
-154.5%
Q1 25
61.1%
-14.8%
Q4 24
64.2%
-18.6%
Q3 24
60.0%
-9.4%
Q2 24
60.1%
-17.3%
Q1 24
59.9%
-13.8%
Net Margin
IBOC
IBOC
MYGN
MYGN
Q4 25
62.3%
Q3 25
49.7%
-13.3%
Q2 25
48.1%
-155.1%
Q1 25
48.9%
-0.1%
Q4 24
71.5%
Q3 24
47.1%
-10.4%
Q2 24
46.7%
-17.4%
Q1 24
47.3%
-12.9%
EPS (diluted)
IBOC
IBOC
MYGN
MYGN
Q4 25
$1.71
$-0.09
Q3 25
$1.74
$-0.29
Q2 25
$1.61
$-3.57
Q1 25
$1.56
$0.00
Q4 24
$1.85
$-0.47
Q3 24
$1.60
$-0.24
Q2 24
$1.56
$-0.41
Q1 24
$1.56
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBOC
IBOC
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$5.5B
$149.6M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$3.3B
$368.0M
Total Assets
$16.6B
$706.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBOC
IBOC
MYGN
MYGN
Q4 25
$5.5B
$149.6M
Q3 25
$5.6B
$145.4M
Q2 25
$5.8B
$74.4M
Q1 25
$5.6B
$91.8M
Q4 24
$5.4B
$102.4M
Q3 24
$5.8B
$99.9M
Q2 24
$5.7B
$97.3M
Q1 24
$5.7B
$104.3M
Total Debt
IBOC
IBOC
MYGN
MYGN
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IBOC
IBOC
MYGN
MYGN
Q4 25
$3.3B
$368.0M
Q3 25
$3.1B
$372.8M
Q2 25
$3.0B
$388.1M
Q1 25
$2.9B
$704.9M
Q4 24
$2.8B
$701.1M
Q3 24
$2.7B
$731.7M
Q2 24
$2.6B
$740.5M
Q1 24
$2.5B
$760.0M
Total Assets
IBOC
IBOC
MYGN
MYGN
Q4 25
$16.6B
$706.6M
Q3 25
$16.6B
$728.1M
Q2 25
$16.5B
$677.3M
Q1 25
$16.3B
$1.0B
Q4 24
$15.7B
$1.0B
Q3 24
$15.9B
$1.1B
Q2 24
$15.5B
$1.1B
Q1 24
$15.4B
$1.1B
Debt / Equity
IBOC
IBOC
MYGN
MYGN
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBOC
IBOC
MYGN
MYGN
Operating Cash FlowLast quarter
$491.1M
$10.6M
Free Cash FlowOCF − Capex
$472.9M
FCF MarginFCF / Revenue
217.2%
Capex IntensityCapex / Revenue
8.3%
Cash ConversionOCF / Net Profit
4.59×
TTM Free Cash FlowTrailing 4 quarters
$809.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBOC
IBOC
MYGN
MYGN
Q4 25
$491.1M
$10.6M
Q3 25
$115.2M
$21.1M
Q2 25
$95.5M
$-13.6M
Q1 25
$140.5M
$-16.3M
Q4 24
$473.9M
$6.6M
Q3 24
$116.5M
$700.0K
Q2 24
$107.2M
$2.6M
Q1 24
$135.4M
$-18.6M
Free Cash Flow
IBOC
IBOC
MYGN
MYGN
Q4 25
$472.9M
Q3 25
$112.2M
Q2 25
$91.6M
Q1 25
$133.1M
Q4 24
$459.8M
Q3 24
$109.6M
Q2 24
$104.9M
Q1 24
$128.9M
FCF Margin
IBOC
IBOC
MYGN
MYGN
Q4 25
217.2%
Q3 25
51.5%
Q2 25
44.0%
Q1 25
67.1%
Q4 24
220.8%
Q3 24
51.7%
Q2 24
50.5%
Q1 24
62.6%
Capex Intensity
IBOC
IBOC
MYGN
MYGN
Q4 25
8.3%
Q3 25
1.3%
Q2 25
1.9%
Q1 25
3.7%
Q4 24
6.8%
Q3 24
3.3%
Q2 24
1.1%
Q1 24
3.2%
Cash Conversion
IBOC
IBOC
MYGN
MYGN
Q4 25
4.59×
Q3 25
1.06×
Q2 25
0.95×
Q1 25
1.45×
Q4 24
4.12×
Q3 24
1.17×
Q2 24
1.11×
Q1 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons